JP2015521992A - 筋萎縮性側索硬化症の治療における抗Ｎｏｇｏ−Ａ抗体の最適投与レジメン - Google Patents

筋萎縮性側索硬化症の治療における抗Ｎｏｇｏ−Ａ抗体の最適投与レジメン Download PDF

Info

Publication number
JP2015521992A
JP2015521992A JP2015519214A JP2015519214A JP2015521992A JP 2015521992 A JP2015521992 A JP 2015521992A JP 2015519214 A JP2015519214 A JP 2015519214A JP 2015519214 A JP2015519214 A JP 2015519214A JP 2015521992 A JP2015521992 A JP 2015521992A
Authority
JP
Japan
Prior art keywords
nogo
antibody
colocalization
days
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015519214A
Other languages
English (en)
Japanese (ja)
Inventor
ブルマン，ジョナサン
クルル，デーヴィット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2015521992A publication Critical patent/JP2015521992A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015519214A 2012-07-05 2013-07-03 筋萎縮性側索硬化症の治療における抗Ｎｏｇｏ−Ａ抗体の最適投与レジメン Withdrawn JP2015521992A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668134P 2012-07-05 2012-07-05
US61/668,134 2012-07-05
PCT/EP2013/064063 WO2014006105A1 (en) 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
JP2015521992A true JP2015521992A (ja) 2015-08-03

Family

ID=48741180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519214A Withdrawn JP2015521992A (ja) 2012-07-05 2013-07-03 筋萎縮性側索硬化症の治療における抗Ｎｏｇｏ−Ａ抗体の最適投与レジメン

Country Status (10)

Country Link
EP (1) EP2870177A1 (enExample)
JP (1) JP2015521992A (enExample)
KR (1) KR20150036398A (enExample)
CN (1) CN104395343A (enExample)
AU (1) AU2013285493A1 (enExample)
BR (1) BR112014032987A2 (enExample)
CA (1) CA2876284A1 (enExample)
IN (1) IN2014KN02952A (enExample)
RU (1) RU2014150265A (enExample)
WO (1) WO2014006105A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279751B1 (ko) * 2019-06-28 2021-07-21 경북대학교 산학협력단 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법
KR102409771B1 (ko) * 2020-06-17 2022-06-16 경북대학교 산학협력단 Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법
WO2026041734A1 (en) * 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10336350B4 (de) 2003-08-08 2007-10-31 Westfalia Separator Ag Vollmantel-Schneckenzentrifuge, mit Schälscheibe
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
DK1711530T3 (da) 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP5698534B2 (ja) 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US20110268729A1 (en) 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist

Also Published As

Publication number Publication date
RU2014150265A (ru) 2016-08-27
KR20150036398A (ko) 2015-04-07
IN2014KN02952A (enExample) 2015-05-08
BR112014032987A2 (pt) 2017-06-27
CA2876284A1 (en) 2014-01-09
WO2014006105A1 (en) 2014-01-09
EP2870177A1 (en) 2015-05-13
CN104395343A (zh) 2015-03-04
AU2013285493A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
US7785587B2 (en) Therapeutic methods for muscular or neuromuscular disorders
US20200308287A1 (en) Wnt surrogate molecules and uses thereof
TWI705824B (zh) 治療阿茲海默症之方法
US20200216533A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
US20100055098A1 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
KR20150048877A (ko) 항체 제제 및 이의 용도
JP2021509813A (ja) 持効性かつ低毒性の組替え型の抗ｖｅｇｆヒト化単クローン抗体及びその調製方法
CN114019170A (zh) 用于阿尔茨海默氏病的高剂量治疗
US20250011416A1 (en) Methods for the treatment of cardiovascular disease
JP2015521992A (ja) 筋萎縮性側索硬化症の治療における抗Ｎｏｇｏ−Ａ抗体の最適投与レジメン
JP2008539266A (ja) 下位運動ニューロン疾患の治療方法およびそれを含む組成物
US20200031924A1 (en) Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
TWI807338B (zh) 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
US20170233467A1 (en) Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
EP3916015A1 (en) Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
HK40068762A (en) High dose treatments for alzheimer's disease
HK40067504A (en) High dose treatments for alzheimer's disease
HK1261507A1 (en) High dose treatments for alzheimer's disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160704

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160719